LianBio announces departure of both its CEO and CFO

Princeton-based biotechnology company LianBio on Tuesday named board member Adam Stone, chief investment officer of Perceptive Advisors, as its interim CEO after CEO Yizhe Wang, who assumed the post in May 2021, resigned to pursue other opportunities, the company said.

“Under Yizhe’s leadership, LianBio built a comprehensive cross-border platform for drug development, advanced multiple programs into pivotal Phase 3 trials, developed a commercial launch infrastructure designed to maximize patient access to innovative new medicines, and executed transformative strategic transactions,” Konstantin Poukalov, executive chairman of the LianBio board of directors, said. “I thank Yizhe for his many contributions to LianBio and look forward to partnering with him on his future endeavors.”

Additionally, the firm announced that Yi Larson, chief financial officer, also has resigned to pursue other opportunities. In connection with her departure, the LianBio board of directors has appointed Ehong “Maggie” Gu, current vice president, head of global finance, as interim CFO.

“We are grateful to Yi for her many contributions to strategic initiatives at LianBio and wish her continued success in her next role,” Poukalov said.